Medtronic Financial Statements (MDT)
|
|
|
|
Report date
|
|
|
23.06.2022 |
30.04.2023 |
22.06.2023 |
30.04.2024 |
20.06.2024 |
|
19.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
31 686 |
31 227 |
31 227 |
|
32 364 |
|
32 822 |
|
Operating Income, bln rub |
|
|
5 752 |
5 485 |
5 485 |
|
5 144 |
|
4 211 |
|
EBITDA, bln rub |
? |
|
9 554 |
9 042 |
8 475 |
|
9 056 |
|
6 614 |
|
Net profit, bln rub |
? |
|
5 039 |
3 758 |
3 758 |
|
3 676 |
|
4 009 |
|
|
OCF, bln rub |
? |
|
7 346 |
6 039 |
6 039 |
|
6 787 |
|
5 707 |
|
CAPEX, bln rub |
? |
|
1 368 |
1 459 |
1 459 |
|
1 587 |
|
1 870 |
|
FCF, bln rub |
? |
|
5 978 |
4 580 |
4 580 |
|
5 200 |
|
3 837 |
|
Dividend payout, bln rub
|
|
|
3 383 |
3 616 |
3 616 |
|
3 666 |
|
3 606 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
Dividend payout ratio, %
|
|
|
67.1% |
96.2% |
96.2% |
|
99.7% |
|
89.9% |
|
|
OPEX, bln rub |
|
|
15 633 |
14 678 |
14 678 |
|
16 129 |
|
14 328 |
|
Cost of production, bln rub |
|
|
10 145 |
10 719 |
10 719 |
|
12 911 |
|
12 697 |
|
R&D, bln rub |
|
|
2 746 |
2 696 |
2 696 |
|
2 735 |
|
2 724 |
|
Interest expenses, bln rub |
|
|
553.0 |
636.0 |
636.0 |
|
719.0 |
|
745.0 |
|
|
Assets, bln rub |
|
|
90 981 |
90 948 |
90 948 |
89 981 |
89 981 |
|
90 042 |
|
Net Assets, bln rub |
? |
|
52 551 |
51 483 |
51 483 |
50 214 |
50 214 |
|
48 494 |
|
Debt, bln rub |
|
|
24 114 |
24 364 |
24 364 |
25 024 |
26 047 |
|
28 326 |
|
Cash, bln rub |
|
|
10 573 |
7 959 |
7 959 |
8 005 |
8 005 |
|
1 394 |
|
Net debt, bln rub |
|
|
13 541 |
16 405 |
16 405 |
17 019 |
18 042 |
|
26 932 |
|
|
Ordinary share price, rub |
|
|
104.4 |
91.0 |
91.0 |
80.2 |
79.7 |
|
72.0 |
|
Number of ordinary shares, mln |
|
|
1 342 |
1 330 |
1 330 |
|
1 328 |
|
1 282 |
|
|
Market cap, bln rub |
|
|
140 093 |
120 945 |
120 945 |
0 |
105 871 |
|
92 333 |
|
EV, bln rub |
? |
|
153 634 |
137 350 |
137 350 |
17 019 |
123 913 |
|
119 265 |
|
Book value, bln rub |
|
|
-3 546 |
-4 786 |
-4 786 |
9 228 |
-3 997 |
|
-5 090 |
|
|
EPS, rub |
? |
|
3.75 |
2.83 |
2.83 |
|
2.77 |
|
3.13 |
|
FCF/share, rub |
|
|
4.45 |
3.44 |
3.44 |
|
3.92 |
|
2.99 |
|
BV/share, rub |
|
|
-2.64 |
-3.60 |
-3.60 |
|
-3.01 |
|
-3.97 |
|
|
EBITDA margin, % |
? |
|
30.2% |
29.0% |
27.1% |
|
28.0% |
|
20.2% |
|
Net margin, % |
? |
|
15.9% |
12.0% |
12.0% |
|
11.4% |
|
12.2% |
|
FCF yield, % |
? |
|
4.27% |
3.79% |
3.79% |
0.00% |
4.91% |
|
4.16% |
|
ROE, % |
? |
|
9.59% |
7.30% |
7.30% |
0.00% |
7.32% |
|
8.27% |
|
ROA, % |
? |
|
5.54% |
4.13% |
4.13% |
0.00% |
4.09% |
|
4.45% |
|
|
P/E |
? |
|
27.8 |
32.2 |
32.2 |
|
28.8 |
|
23.0 |
|
P/FCF |
|
|
23.4 |
26.4 |
26.4 |
|
20.4 |
|
24.1 |
|
P/S |
? |
|
4.42 |
3.87 |
3.87 |
|
3.27 |
|
2.81 |
|
P/BV |
? |
|
-39.5 |
-25.3 |
-25.3 |
0.00 |
-26.5 |
|
-18.1 |
|
EV/EBITDA |
? |
|
16.1 |
15.2 |
16.2 |
|
13.7 |
|
18.0 |
|
Debt/EBITDA |
|
|
1.42 |
1.81 |
1.94 |
|
1.99 |
|
4.07 |
|
|
R&D/CAPEX, % |
|
|
200.7% |
184.8% |
184.8% |
|
172.3% |
|
145.7% |
|
|
CAPEX/Revenue, % |
|
|
4.32% |
4.67% |
4.67% |
|
4.90% |
|
5.70% |
|
| Medtronic shareholders |
